Home/Pipeline/Etigilimab (MPH313)

Etigilimab (MPH313)

Advanced Solid Tumors

Phase 1bOut-licensed

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1b

Status

Out-licensed

Company

Mereo BioPharma

About Mereo BioPharma

Mereo BioPharma is a UK-based biopharma founded in 2015 with a mission to deliver impactful therapies for rare diseases with limited treatment options. Its core strategy involves identifying, in-licensing, and developing late-stage clinical assets that have been deprioritized by larger pharmaceutical companies, leveraging deep industry relationships and a patient-centric approach. Key achievements include a foundational asset acquisition from Novartis, a transformative 2019 merger with OncoMed that secured a NASDAQ listing, and a strategic partnership with Ultragenyx for its lead osteogenesis imperfecta program.

View full company profile

Therapeutic Areas

Rare Diseases Genetic Disorders

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
M8891	Merck KGaA	Phase 1/2	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BP1001-A	Bio-Path Holdings	Phase 1	Active
FS222	F-star Therapeutics	Phase 1	Active (status post-acquisition)
FS120	F-star Therapeutics	Phase 1	Active (status post-acquisition)
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active